• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗毒蕈碱药物治疗膀胱过度活动症的临床应用概述。

An overview of the clinical use of antimuscarinics in the treatment of overactive bladder.

作者信息

Athanasopoulos Anastasios, Giannitsas Konstantinos

机构信息

Urodynamic Urology Unit, Department of Urology, Medical School, University of Patras, 26500 Patra, Greece.

出版信息

Adv Urol. 2011;2011:820816. doi: 10.1155/2011/820816. Epub 2011 Jun 7.

DOI:10.1155/2011/820816
PMID:21687579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3114080/
Abstract

Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients' quality of life. Antimuscarinics are generally well tolerated with mild and predictable side effects. Available antimuscarinics have small, yet statistically significant, differences in their efficacy and tolerability profiles. In clinical practice, finding the agent that offers the optimum balance of efficacy and side effects for an individual patient remains the major challenge.

摘要

膀胱过度活动症是一种常见且令人困扰的病症。抗毒蕈碱药物作为一类药物,是膀胱过度活动症药物治疗的基石。它们能显著改善症状和患者的生活质量。抗毒蕈碱药物一般耐受性良好,副作用轻微且可预测。现有的抗毒蕈碱药物在疗效和耐受性方面存在微小但具有统计学意义的差异。在临床实践中,为个体患者找到疗效和副作用达到最佳平衡的药物仍然是主要挑战。

相似文献

1
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder.抗毒蕈碱药物治疗膀胱过度活动症的临床应用概述。
Adv Urol. 2011;2011:820816. doi: 10.1155/2011/820816. Epub 2011 Jun 7.
2
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.米拉贝隆对比抗胆碱能单药治疗或联合治疗用于治疗膀胱过度活动症的疗效和耐受性:一项系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):324-333. doi: 10.1016/j.eururo.2018.03.020. Epub 2018 Apr 23.
3
The medical treatment of overactive bladder, including current and future treatments.膀胱过度活动症的治疗,包括当前和未来的治疗方法。
Expert Opin Pharmacother. 2011 May;12(7):1041-55. doi: 10.1517/14656566.2011.554399. Epub 2011 Feb 8.
4
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.联合药物治疗过度活动膀胱患者的疗效和安全性:快速证据评估。
Eur Urol. 2019 Dec;76(6):767-779. doi: 10.1016/j.eururo.2019.07.010. Epub 2019 Aug 13.
5
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.抗毒蕈碱药物治疗对膀胱过度活动症的影响:系统评价与荟萃分析的更新
Eur Urol. 2008 Sep;54(3):543-62. doi: 10.1016/j.eururo.2008.06.047. Epub 2008 Jun 20.
6
The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.抗毒蕈碱治疗对膀胱过度活动症的影响:一项系统评价与荟萃分析。
Eur Urol. 2005 Jul;48(1):5-26. doi: 10.1016/j.eururo.2005.02.024. Epub 2005 Mar 22.
7
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.老年患者膀胱过度活动症的口服药物治疗:米拉贝隆作为抗毒蕈碱药物的潜在替代药物
Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17.
8
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?抗毒蕈碱药物与选择性β3肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症的疗效和耐受性比较:哪种作为初始治疗更可取?
Low Urin Tract Symptoms. 2018 May;10(2):158-166. doi: 10.1111/luts.12153. Epub 2016 Dec 23.
9
Fesoterodine for the treatment of urinary incontinence and overactive bladder.非索罗定治疗尿失禁和膀胱过度活动症。
Ther Clin Risk Manag. 2009;5:869-76. doi: 10.2147/tcrm.s6483. Epub 2009 Nov 18.
10
Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.抗毒蕈碱药物治疗膀胱过度活动症的基础和临床方面。
Pharmacol Ther. 2018 Sep;189:130-148. doi: 10.1016/j.pharmthera.2018.04.010. Epub 2018 Apr 27.

引用本文的文献

1
An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder.一项关于米拉贝隆在中国膀胱过度活动症患者中开展的开放标签、随机、上市后研究。
Asian J Urol. 2025 Jan;12(1):79-86. doi: 10.1016/j.ajur.2024.04.007. Epub 2024 Jul 27.
2
Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study.开发和验证预测女性急迫性和/或急迫性尿失禁治疗模式的模型:下尿路功能障碍症状研究网络观察队列研究。
Neurourol Urodyn. 2023 Aug;42(6):1214-1226. doi: 10.1002/nau.25222. Epub 2023 Jun 3.
3
Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study.在症状性下尿路功能障碍研究网络观察性队列研究中,女性尿急和/或急迫性尿失禁的治疗模式。
Neurourol Urodyn. 2023 Jan;42(1):194-204. doi: 10.1002/nau.25067. Epub 2022 Oct 23.
4
Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.维贝格隆与米拉贝隆及抗胆碱能药物治疗膀胱过度活动症的长期疗效和安全性:一项系统评价和网状Meta分析
Drugs Context. 2022 Oct 10;11. doi: 10.7573/dic.2022-4-2. eCollection 2022.
5
Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data.抗毒蕈碱药物用于治疗多发性硬化症中的神经源性膀胱过度活动症:真实世界数据。
Ther Adv Urol. 2022 Sep 24;14:17562872221122484. doi: 10.1177/17562872221122484. eCollection 2022 Jan-Dec.
6
The Association Between Urinary Tract Infection and Overactive Bladder Treatment.尿路感染与膀胱过度活动症治疗之间的关联
Front Pharmacol. 2022 Jan 25;12:803970. doi: 10.3389/fphar.2021.803970. eCollection 2021.
7
Potential Role for Combined Subtype-Selective Targeting of M and M Muscarinic Receptors in Gastrointestinal and Liver Diseases.M 型和 M 型毒蕈碱受体联合亚型选择性靶向在胃肠道和肝脏疾病中的潜在作用
Front Pharmacol. 2021 Nov 4;12:786105. doi: 10.3389/fphar.2021.786105. eCollection 2021.
8
Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review.β3肾上腺素能受体激动剂用于治疗良性前列腺增生男性的下尿路症状:一项系统评价
Int Neurourol J. 2021 Sep;25(3):182-191. doi: 10.5213/inj.2142068.034. Epub 2021 Sep 30.
9
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.进行性核上性麻痹和皮质基底节综合征临床管理的最佳实践:CurePSP护理中心的共识声明
Front Neurol. 2021 Jul 1;12:694872. doi: 10.3389/fneur.2021.694872. eCollection 2021.
10
Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.老年痴呆症和膀胱过度活动症患者中抗毒蕈碱药物的使用:一项针对医疗保险受益人的研究。
Curr Med Res Opin. 2021 Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899. Epub 2021 May 13.

本文引用的文献

1
Antimuscarinic mechanisms and the overactive detrusor: an update.抗毒蕈碱机制与逼尿肌过度活动:更新。
Eur Urol. 2011 Mar;59(3):377-86. doi: 10.1016/j.eururo.2010.11.040. Epub 2010 Dec 8.
2
Trospium chloride is undetectable in the older human central nervous system.在老年人类中枢神经系统中无法检测到氯化曲司氯铵。
J Am Geriatr Soc. 2010 Aug;58(8):1618-9. doi: 10.1111/j.1532-5415.2010.02988.x.
3
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.非索罗定控释片较托特罗定控释片具有更快起效的卓越疗效:一项前瞻性、头对头、安慰剂对照试验。
BJU Int. 2011 May;107(9):1432-40. doi: 10.1111/j.1464-410X.2010.09640.x. Epub 2010 Sep 21.
4
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.一项开放性、剂量灵活的研究表明,为患者优化的非索罗定剂量可改善膀胱症状。
BJU Int. 2011 Feb;107(4):603-11. doi: 10.1111/j.1464-410X.2010.09587.x. Epub 2010 Sep 22.
5
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.过度活跃膀胱药物与便秘:一项随机、安慰剂对照试验的荟萃分析。
Dig Dis Sci. 2011 Jan;56(1):7-18. doi: 10.1007/s10620-010-1313-3. Epub 2010 Jul 2.
6
Thorough QT study of the effect of fesoterodine on cardiac repolarization.非索罗定对心脏复极化影响的全面QT研究。
Int J Clin Pharmacol Ther. 2010 May;48(5):309-18. doi: 10.5414/cpp48309.
7
A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.一项关于缓释托特罗定治疗对瑞典膀胱过度活动症患者健康相关生活质量影响的前瞻性观察研究。
Scand J Urol Nephrol. 2010 Apr;44(3):138-46. doi: 10.3109/00365591003709468.
8
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.非索罗定与托特罗定延长释放治疗膀胱过度活动症的比较:一项头对头安慰剂对照试验。
BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.
9
Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?抗毒蕈碱药物和膀胱出口梗阻:从禁忌症到适应证?
Neurourol Urodyn. 2010;29 Suppl 1:S46-50. doi: 10.1002/nau.20807.
10
Overactive bladder medication adherence when medication is free to patients.患者免费获得药物时,过度膀胱药物的用药依从性。
J Urol. 2010 Mar;183(3):1077-81. doi: 10.1016/j.juro.2009.11.026. Epub 2010 Jan 21.